Cleerly presented primary results of PARAMOUNT, a randomized trial of 530 patients at 21 sites comparing AI-QCT plaque guided care with stress test guided usual care, as Late Breaking Science at AHA 2026. The trial met its composite primary endpoint at 180 days with a win ratio of 2.00 (p<0.0001), and lipid lowering therapy use rose from 31 to 75 percent in the AI-QCT arm versus 32 to 47 percent with usual care. Results are not yet peer reviewed.
Our readThis is randomized outcome level evidence for AI-QCT guided care rather than accuracy data alone, which supports payer coverage arguments and pathway changes away from functional stress testing. Buyers should note the 180 day horizon and the not yet peer reviewed status.